首页> 外文期刊>The Journal of Physiology >Role of endogenous endothelin in the regulation of basal coronary tone in the rat.
【24h】

Role of endogenous endothelin in the regulation of basal coronary tone in the rat.

机译:内源性内皮素在大鼠基础冠状动脉张力调节中的作用。

获取原文
获取原文并翻译 | 示例
           

摘要

1. Coronary vascular tone is a vital factor that regulates the delivery of oxygen to cardiac muscle. We tested the hypothesis that basal coronary tone may depend on the release of an endogenous vasoconstrictor peptide, endothelin (ET). 2. Using an isolated, Krebs solution-perfused rat heart we measured the changes in coronary flow following the administration over a 30 min period of the ET antagonists Ro61-0612 (mixed ETA/ETB), PD155080 (ETA) and BQ788 (ETB). 3. In a second series of experiments, hearts were randomly assigned to perfusion with plain Krebs solution, or with Krebs solution to which L-NAME and/or indomethacin had been added. The effect on coronary flow following the addition of Ro61-0612 was then measured. 4. Perfusion with Ro61-0612 (10-4 M) alone increased coronary flow by 57.8 % vs. control (P = 0.00001). PD155080 (10-4 M) increased coronary flow by 28.9 % (P = 0.009), whereas BQ788 had no effect on coronary flow. 5. In the second series of experiments, Ro61-0612 increased coronary flow by 6.6 +/- 0.8 ml min-1 in hearts perfused with plain Krebs solution, by 3.8 +/- 0.8 ml min-1 in hearts to which both L-NAME and indomethacin had been added, by 3.3 +/- 0.7 ml min-1 in hearts to which L-NAME had been added, and by 6. 9 +/- 0.5 ml min-1 in hearts to which indomethacin had been added to the Krebs buffer. 6. In hearts perfused with Krebs solution alone, nitric oxide (NO) release into the coronary sinus increased from 219. 8 to 544.9 pmol min-1 g-1 following the addition of Ro61-0612 (P = 0. 06). There was no detectable release of NO from hearts perfused with L-NAME alone or in combination with indomethacin either before or after the addition of Ro61-0612. 7. We conclude that endogenous ET plays a role in coronary tone mediated via ETA receptors. This vasodilatation is partially due to an increase in endogenous NO release. However, a significant vasodilatation is still seen following the inhibition of NO synthesis. We propose that basal coronary tone depends on a balance between the endogenous release of vasodilators such as NO and vasoconstrictors such as ET.
机译:1.冠状血管张力是调节氧气向心肌输送的重要因素。我们测试了基础冠状动脉张力可能取决于内源性血管收缩肽内皮素(ET)释放的假说。 2.使用分离的Krebs溶液灌流的大鼠心脏,我们在ET拮抗剂Ro61-0612(ETA / ETB混合),PD155080(ETA)和BQ788(ETB)施用30分钟后测量了冠状动脉血流的变化。 。 3.在第二系列实验中,将心脏随机分配至普通Krebs溶液或已添加L-NAME和/或消炎痛的Krebs溶液灌注。然后测量添加Ro61-0612后对冠脉血流的影响。 4.与对照相比,仅用Ro61-0612(10-4 M)灌注可使冠脉流量增加了57.8%(P = 0.00001)。 PD155080(10-4 M)使冠状动脉血流量增加了28.9%(P = 0.009),而BQ788对冠状动脉血流量没有影响。 5.在第二系列实验中,Ro61-0612在用普通Krebs溶液灌注的心脏中使冠状动脉血流增加6.6 +/- 0.8 ml min-1,在两个L-均向其灌注的心脏中使冠状动脉血流量增加3.8 +/- 0.8 ml min-1 NAME和吲哚美辛的添加量为:添加了L-NAME的心脏浓度为3.3 +/- 0.7 ml min-1,添加了吲哚美辛的浓度为6. 9 +/- 0.5 ml min-1克雷布斯缓冲区。 6.在仅用Krebs溶液灌注的心脏中,添加Ro61-0612后,向冠状窦中释放的一氧化氮(NO)从219. 8增加到544.9 pmol min-1 g-1(P = 0. 06)。在添加Ro61-0612之前或之后,单独灌注L-NAME或与吲哚美辛组合的心脏均未检测到NO释放。 7.我们得出结论,内源性ET在通过ETA受体介导的冠脉张力中起作用。这种血管扩张部分是由于内源性NO释放增加所致。然而,在抑制NO合成后,仍然观察到明显的血管舒张。我们建议,基础冠状动脉张力取决于血管扩张剂(例如NO)和血管收缩剂(例如ET)的内源性释放之间的平衡。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号